
Atrial Fibrillation News and Views Hamid Ikram

6


Why is AF important?

1 of 3 modern CVS Epidemics


HYPERTENSION
 HEART FAILURE
 ATRIAL EIRRULATION



AF Is Associated With Increased Mortality




Many Hospital Days = \$\$\$\$\$.





Source: <u>Current Problems in Cardiology 2000; 25:413-524</u> Copyright © 2000 Mosby, Inc. <u>Terms and Conditions</u> # 1 of Obama Administration's Goals in Comparative Effectiveness Research



Causes, Consequences and Natural History

Table 1.2 Common cardiac and non-cardiac causes of AF

Cardiac causes of AF

Common cardiac causes: ischaemic heart disease rheumatic heart disease hypertension sick sinus syndrome pre-excitation syndromes (eg Wolff–Parkinson–White).

Less common cardiac causes: cardiomyopathy or heart muscle disease pericardial disease (including effusion and constrictive pericarditis) atrial septal defect atrial myxoma.

Non-cardiac causes of AF

Acute infections, especially pneumonia

Electrolyte depletion

Lung carcinoma


Other intrathoracic pathology (eg pleural effusion)

Pulmonary embolism

Thyrotoxicosis

SSS ie Ageing
Obesity
Alcohol and Drugs- therapeutic esp AAD and of course the others

Incidence increases with age



Source: <u>Current Problems in Cardiology 2000; 25:413-524</u> Copyright © 2000 Mosby, Inc. <u>Terms and Conditions</u>

The Problems of AF

Consequences of AF

Hospitalizations:

- Most common arrhythmia requiring hospitalization
- 2-3x ↑ risk for hospitalization

Thromboembolism:

- Stroke: 4.5x ↑ risk
- Microemboli: reduced cognitive function
- Prothrombotic state

Reduced QoL:

- Palpitations, dyspnea, fatigue,
 - ↓ exercise tolerance

Mortality:


- 2x risk independent of comorbid CV disease
- Sudden death in heart failure and HCM

Impaired Hemodynamics:

- Loss of atrial kick
- Irregular ventricular contractions
- Heart failure
- Tachycardia-induced cardiomyopathy

Natural History of AF

Progression of AF



It is a progressive disorder

Management Strategies

Rate or Rhythm ?

Rate vs Rhythm Control

Sinus Rhythm Strategy: Who Are Appropriate Candidates?

- Highly symptomatic with AF
- First episode
- Reversible cause
- Young age
- Symptomatic despite rate control
- Rate-related cardiomyopathy
- LV dysfunction/CHF
- Diastolic dysfunction with symptoms
- HCM or aortic stenosis
- Prior embolic stroke or TIA

Rate vs Rhythm Control

Strategies for Restoring and Maintaining Normal Sinus Rhythm

- Electrical or pharmacologic cardioversion
- Treatment of reversible causes
- AAD therapy:


Beware of 'Proarrhythmia'

- Intermittent
- Continuous "Pill in Pocket"
- Catheter ablation:
 - PVI (paroxysmal)
 - PVI + substrate modification (persistent)
- Surgical ablation

Pros and Cons of each


AAD for SR Mainteinence

SAFE-T: Sotalol vs Amiodarone



Drugs are Dangerous

AFFIRM: Independent Predictors of Survival



The risks of AADs counterbalance the benefits of sinus rhythm.

Rate vs Rhythm Control

Conclusions Rate control is not inferior to rhythm control for the prevention of death and morbidity from cardiovascular causes and may be appropriate therapy in patients with a recurrence of persistent atrial fibrillation after electrical cardioversion. (N Engl J Med 2002;347:1834-40.)

The RACE Trial

New Pharmacologic Agents for AF

- Multi-ion channel blockers:
 Other ion channel blockers
 - Dronedarone
 - Budiodarone
- Atrial-selective AADs:
 - I_{Kur}- , I_{to} and I_{KACh} blocker
 - Atrial-selective Na channel blocker
 - Histamine (5-HT₄) receptor antagonist

- Other mechanisms
- Upstream therapies:
 - Statins
 - ACEI/ARB
 - Omega-3 fatty acids
 - Anti-inflammatory drugs

Intermittent AF

What Is the Measure of Successful Treatment of AF?

 As with heart failure or angina, success in managing AF is defined as a decrease in:



- Recurrence of AF is not ipso facto drug failure
- AAD efficacy should not be measured simply by time to first recurrence of AF
- Occasional recurrence of AF may be acceptable

The big issue-AF and Stroke

□ Patients with sustained non-rheumatic AF have 5-7 times the risk of stroke than the GP

The risk of stroke and non- CNS embolism are similar in sustained and intermittent AF

Stroke Risk in Intermittent AF

CONCLUSIONS

In this large cohort of AF patients given aspirin, those with intermittent AF had stroke rates similar to patients with sustained AF and similar stroke risk factors. Many elderly patients with recurrent intermittent AF have substantial rates of stroke and likely benefit from anticoagulation. High-risk patients with intermittent AF can be identified using the same clinical criteria that apply to patients with sustained AF.

CHADS2 Score and Stroke

Annual Stroke Risk				
CHADS ₂ Score	Stroke Risk %	95% CI		
0	1.9	1.2-3.0		
1	2.8	2.0-3.8		
2	4.0	3.1-5.1		
3	5.9	4.6-7.3		
4	8.5	6.3-11.1		
5	12.5	8.2-17.5		
6	18.2	10.5-27.4		


C= CHF H= Hypertension A= Age > 75 D= Diabetes S= Prior Stroke- 2 point

Stroke risk in patients with nonvalvular AF not treated with anticoagulation according to the CHADS₂ index


- CHADS₂ risk criteria and scoring
 - Prior stroke or TIA 2 points
 Age > 75 years 1 point
 - Hypertension 1 point
 - Diabetes mellitus
 1 point
 - Heart failure 1 point

Patients (n = 1733)	Patients (n = 1733) Adjusted stroke rate (%/year)* (95% CI)	
120	1.9 (1.2–3.0)	0
463	2.8 (2.0–3.8)	1
523	4.0 (3.1–5.1)	2
337	5.9 (4.6–7.3)	3
220	8.5 (6.3–11.1)	4
65	12.5 (8.2–17.5)	5
5	18.2 (10.5–27.4)	6







Stroke: Adjusted-Dose Warfarin vs Placebo/Control



Stroke: Antiplatelet Agents vs Placebo/Control



Stroke: Adjusted-Dose Warfarin vs Antiplatelet Rx



*Includes 2 small trials (n = 106) with only 2 strokes; does not include SPAF III (n = 1044) and part of AFASAK II (n = 341) where antiplatelet groups also received warfarin



Reproduced with permission from:




Hart RG, et al. Ann Intern Med. 2007;146:857-867.


POISON NOT TO BE TAKEN




Who is afraid of big bad Warfarin ?



Warfarin Use According to CHADS₂ Scores




Warfarin Use Over Time



The 'J-curve' of Warfarin Therapy

Optimal INR for Prevention of Stroke and ICH in Relation to Anticoagulation Intensity



Adapted from Hylek EM. Arch Intern Med. 1994;120:897-902. Odén A, et al. Thromb Res. 2006;117:493-499.

rombosis



Contraindications to warfarin use include:

- Haemorrhagic tendencies and blood dyscrasias
- Past history of intracranial haemorrhage
- Recent history of GI or GU bleeding (previous six months)
- Uncontrolled hypertension
- Severe liver disease
- Alcoholism
- Recurrent unexplained syncope
- Planned surgery
- Pregnancy

AHA Performance Measure AF:

Assessment of thrombotic risk
 Chronic anticoagulation
 Monthly INR measurements





Other aspects to consider when prescribing warfarin include:

- Comorbidities
- Concomitant use of medications
- Poor compliance with medication and monitoring (e.g. cognitive impairment, confusion, mental illness, inability to access services)
- Activities that increase the risk of trauma
- Increased risk of bleeding in elderly people
- Potential for falls
- Changes in diet, supplement use and general wellbeing (e.g. new illness)


Important Messages

Warfarin Reduces Risk of Stroke by 68%


Asprin Reduces Risk of Stroke by 44% (325 mg/ daily)

Combined ASA/Warfarin Saga

Discharge Antithrombotic Therapy



"Watchman"



Your Take Home Message

- One of the 'Big 3 CVS Epidemics"
- Main causes today are CAD, Hypertension, Ageing [SN Disease], Obesity
- Independent cause of increased mortality
- High morbidity
- Rate control as good as rhythm control for QoL and Survival
- Adequate anticoagulation remains a challenge-CHADS score
- Dangers of Warfarin overstated
- New Therapies on the way- BUT long journey to NZ

Results

	AF on admission (n = 14,901)	History of AF only (n = 9918)	No AF (n = 47,715)
Age, median	79	79	72
Women	49	49	50
White	82	81	64
LVEF < 40%	40	42	48
Stroke or TIA	16	16	12
Renal insufficiency	18	21	19
ICD	11	11	9
BNP, median	755	760	928



Piccini JP, et al. J Am Coll Cardiol. 2009;54:1280-1289.



CHADS score and AC

Recommendations for anticoagulation

The following treatment strategies were recommended:[1][2]

Score	Risk	Anticoagulation Therapy	Considerations	
0	Low	Aspirin	Aspirin daily	
1	Moderate	Aspirin or Warfarin	Aspirin daily or raise INR to 2.0-3.0, depending on factors such as patient preference	
2 or greater	Moderate or High	Warfarin	Raise INR to 2.0-3.0, unless contraindicated (e.g. clinically significant GI bleeding, inability to obtain regular INR screening)	